|Day Low/High||7.78 / 8.06|
|52 Wk Low/High||3.32 / 9.38|
I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Good individual traders will produce returns far in excess of anything that traditional Wall Street will earn.
Small-caps have done better than their bigger brethren so far in 2019, and these three stocks are a reason why.
I expect deal volume to have a substantial uptick before the end of 2018 rolls around.
The biotech sector has seen a big rally, but there are still opportunities.
Prospects for acquisition activity in the sector are improving.
Historically, the day before a holiday often has a positive bias, but the algos have killed emotion.
Action runs counter to pattern, leaving market players wondering what to do.
We'll see what happens in the way of reaction to Trump's tax policy this afternoon, but if we sell off I'm likely going to be a buyer.
The fact that many traders weren't well-positioned for Monday's move up is helping to create one-way action this morning.
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
The firms all have drugs they want the feds to bend the rules to approve.
These 2 small-caps have strong pipelines and are becoming analyst darlings.
Small biotech tanked on weak earnings, but still seems promising.
Updates on smaller housing, retail and biotech plays recently mentioned on these pages.
Don't trade the headline numbers, but cash in on those traders that do.
It appears based on the futures that the market's rally will continue today, at least at the open. Personally, I think investors are becoming complacent given what could unfold in Greece over the next week. Everyone seems to be betting that Europe w...